LRRK2 Therapeutics

The other significant gene which acts as a major player in the autosomal dominant PD is the LRRK2. It was first identified in a Japanese population in 2002 and first cloned in 2004.
The great significance of this gene is that it has both kinase activity and GTPase activity encoded within the same molecule. Literature report also suggests that the Kinase activity is governed by the GTPase activity, however, the GTPase activity is normal even if the kinase activity is ablated.
Targeting for small molecule inhibitors for ablation of kinase activity will be a possible therapeutic target for the disease.